These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27492979)

  • 1. Human papillomavirus (HPV): making the case for 'Immunisation for All'.
    Prue G; Lawler M; Baker P; Warnakulasuriya S
    Oral Dis; 2017 Sep; 23(6):726-730. PubMed ID: 27492979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?
    Isaranuwatchai W; Graham DM; Siu LL; Hoch JS
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):763-5. PubMed ID: 25095728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic HPV vaccination: past, present, and future.
    Castle PE; Maza M
    Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of human papillomavirus vaccination.
    Brotherton JM; Ogilvie GS
    Curr Opin Oncol; 2015 Sep; 27(5):399-404. PubMed ID: 26258273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
    Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J
    BMJ; 2015 May; 350():h2016. PubMed ID: 25985328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The disease burden of human papillomavirus in men is substantial and can potentially be prevented].
    Kiellberg Larsen H; Kofoed K; Sand C
    Ugeskr Laeger; 2013 Feb; 175(6):349-53. PubMed ID: 23402241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The first vaccine against cancer: the human papillomavirus vaccine].
    Bősze P
    Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
    Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic human papillomavirus vaccines: past, present and future.
    Anderson LA
    Pathology; 2012 Jan; 44(1):1-6. PubMed ID: 22157686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.
    Guo T; Eisele DW; Fakhry C
    Cancer; 2016 Aug; 122(15):2313-23. PubMed ID: 27152637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA; Segal SV; Méndez JH
    Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.
    Graham DM; Isaranuwatchai W; Habbous S; de Oliveira C; Liu G; Siu LL; Hoch JS
    Cancer; 2015 Jun; 121(11):1785-92. PubMed ID: 25867018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?
    Osazuwa-Peters N
    Vaccine; 2013 Nov; 31(47):5500-5. PubMed ID: 24095883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?
    Takes RP; Wierzbicka M; D'Souza G; Jackowska J; Silver CE; Rodrigo JP; Dikkers FG; Olsen KD; Rinaldo A; Brakenhoff RH; Ferlito A
    Oral Oncol; 2015 Dec; 51(12):1057-60. PubMed ID: 26520047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Papillomavirus and Associated Cancers: A Review.
    Jensen JE; Becker GL; Jackson JB; Rysavy MB
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.